Medicare will achieve greater savings on the 15 drugs in its second round of price negotiations than it did in the first round. Despite new challenges, the effort should continue to pay growing dividends.
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine
Hematology/Oncology
|11th Mar, 2026
|The New England Journal of Medicine